Skip to main content

Bumetanide Injection Shortage

Last Updated: July 6, 2024
Status: Current

Products Affected - Description
    • Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 4 mL vial, 10 count, NDC 65219-0570-04
    • Bumetanide injection, Glenmark, 0.25 mg/mL, 4 mL vial, 10 count, NDC 68462-0469-54
Reason for the Shortage
    • Fresenius Kabi has bumetanide injection on shortage due to shipping delays.
    • Glenmark has bumetanide injection on shortage due to manufacturing delays.
    • Hikma has bumetanide injection available.
    • Novadoz did not provide a reason for the shortage.
    • Pfizer has discontinued bumetanide injection in August 2022.
    • Sagent has bumetanide injection available.
Available Products
    • Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 10 mL vial, 10 count, NDC 65219-0570-10
    • Bumetanide injection, Glenmark, 0.25 mg/mL, 10 mL vial, 10 count, NDC 68462-0470-54
    • Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
    • Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
    • Bumetanide injection, Novadoz, 0.25 mg/mL, 10 mL vial, 10 count, NDC 72205-0102-07
    • Bumetanide injection, Novadoz, 0.25 mg/mL, 4 mL vial, 10 count, NDC 72205-0101-07
    • Bumetanide injection, Sagent, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
    • Bumetanide injection, Sagent, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04

Estimated Resupply Dates

    • Fresenius Kabi has bumetanide 0.25 mg/mL 4 mL vials on back order and the company cannot estimate a release date.
    • Glenmark has bumetanide 0.25 mg/mL 4 mL vials on intermittent back order and the company is releasing product as it becomes available.

Updated

Updated July 6, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.